Stephanie Henriquez

Stephanie Henriquez

Auto-generated profile, based on publicly available information

Stephanie Henriquez

Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, Maryland 21205, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RMRobert Millikin
Robert Millikin
CBChristopher L. Bianco
Christopher L. Bianco
CWCorey White
Corey White
SSSimran S. Saund
Simran S. Saund
SHStephanie Henriquez
Stephanie Henriquez
JFJon M. Fukuto
Jon M. Fukuto

1 December 2015 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SSSimran S. Saund
Simran S. Saund
VSVictor Sosa
Victor Sosa
SHStephanie Henriquez
Stephanie Henriquez
QNQ. Nhu N. Nguyen
Q. Nhu N. Nguyen
CBChristopher L. Bianco
Christopher L. Bianco
JFJon M. Fukuto
Jon M. Fukuto

17 June 2019 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
SHSamuel H. Henager
Samuel H. Henager
SHStephanie Henriquez
Stephanie Henriquez
DDDaniel R. Dempsey
Daniel R. Dempsey
PCPhilip Cole
Philip Cole

7 January 2025 in Biochemistry
Verified
Journal Article
Closed access
SHStephanie Henriquez
Stephanie Henriquez
CNCharles R. Nosal
Charles R. Nosal
JKJoseph R. Knoff
Joseph R. Knoff
LCLauren B. Coco
Lauren B. Coco
CMCaren L F Freel Meyers
Caren L F Freel Meyers

2 July 2026 in Biochemistry
Verified
Journal Article
Closed access
SHStephanie Henriquez
Stephanie Henriquez
CNCharles R. Nosal
Charles R. Nosal
LKLydia J. Kramer
Lydia J. Kramer
ETEucolona M. Toci
Eucolona M. Toci
STSara A. Trauth
Sara A. Trauth
CMCaren L F Freel Meyers
Caren L F Freel Meyers

28 June 2025 in ACS Omega
Verified
Journal Article
Open access
AAAmer Al-Khouja
Amer Al-Khouja
SHStephanie Henriquez
Stephanie Henriquez
JHJames J. Hobson
James J. Hobson
JWJennifer A. White
Jennifer A. White
CFCharles Flexner
Charles Flexner
CMCaren L F Freel Meyers
Caren L F Freel Meyers
Long-acting injectable (LAI) antiretroviral (ARV) approaches are needed to address poor adherence to oral drug regimens in the treatment and prevention of human immunodeficiency virus (HIV). We have previously reported semisolid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) that showed extended pharmacokinetic half-lives in vivo. Here, we report the design, synthesis, and evaluation of FTC octyl carbamate prodrugs masked with a variety of bioreversible protecting groups at the 5′-position. We show that 5′-modifications displaying a range of hydrolytic stabilities in biomatrices are compatible with the LAI formulation by the emulsion-templated freeze-drying (ETFD) method. The results demonstrate the feasibility of tuning prodrug activation kinetics while maintaining LAI compatibility, which is critical for the development of nucleoside reverse transcriptase inhibitor (NRTI)-containing LAI-ARV therapies.